Evaluation of the VioOne HIV profile supplemental assay-Reference-Cited by-同舟云学术

Evaluation of the VioOne HIV profile supplemental assay

Published:2024-02-14 Issue:2 Volume:62 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Franz Brian J.¹,Register Heidi²,Sullivan Vickie³,Warber Kimbrough⁴,Granade Timothy C.³,Cornaby Caleb¹,Magee Mark E.⁴,Denny Thomas N.²,Lockwood Don⁵,Schmitz John L.¹^ORCID

Affiliation:

1. Department of Pathology and Laboratory Medicine, UNC-Chapel Hill School of Medicine , Chapel Hill, North Carolina, USA

2. Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina, USA

3. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia, USA

4. Clinical Reference Laboratory, Clinical Reference Laboratory Inc. , Lenexa, Kansas, USA

5. Avioq, Inc. , Research Triangle Park, North Carolina, USA

Abstract

We evaluated the reproducibility, sensitivity, and specificity data for two versions of the VioOne HIV Profile Supplemental Assay and compared these results back to similar results for the Geenius HIV 1/2 Supplemental Assay that are publicly available. Our study concluded that the VioOne HIV Profile Supplemental Assay compared favorably with the Geenius HIV 1/2 Supplemental Assay, thus providing an additional option for clinical laboratories to improve and expand their HIV testing capabilities.

Publisher

American Society for Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/jcm.00836-23

Reference11 articles.

1. UNAIDS . 2022. Global HIV & AIDS statistics - 2022 fact sheet. Available from: https://www.unaids.org/en/resources/fact-sheet

2. Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis

3. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings;Branson BM;MMWR Recomm Rep,2006

4. Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement

5. Incarceration, Sexual Risk-Related Behaviors, and HIV Infection Among Women at Increased Risk of HIV Infection, 20 United States Cities